Search

Your search keyword '"Leiomyoma metabolism"' showing total 1,278 results

Search Constraints

Start Over You searched for: Descriptor "Leiomyoma metabolism" Remove constraint Descriptor: "Leiomyoma metabolism"
1,278 results on '"Leiomyoma metabolism"'

Search Results

1. The in vivo effects of knockdown of long non-coding RNA XIST on fibroid growth and gene expression.

2. Deciphering endometrial dysfunction in patients with uterine myoma using endometrial organoids: a pilot study.

3. Engineered uterine primary myometrial cells with high-mobility group AT-hook 2 overexpression display a leiomyoma-like transcriptional and epigenomic phenotype.

4. Coenzyme Q-10 reduced the aberrant production of extracellular matrix proteins in uterine leiomyomas through transforming growth factor beta 3.

5. First identification of microplastics in human uterine fibroids and myometrium.

6. HMGA2 overexpression induces plasticity in myometrial cells and a transcriptomic profile more similar to that of uterine fibroids.

7. The Functional Role of the Long Non-Coding RNA LINCMD1 in Leiomyoma Pathogenesis.

8. Spatially restricted ecto-5'-nucleotidase expression promotes the growth of uterine leiomyomas by modulating Akt activity.

9. Induction of fibrosis following exposure to bisphenol A and its analogues in 3D human uterine leiomyoma cultures.

10. Altered extracellular matrix-related pathways accelerate the transition from normal to prefibroid myometrium in Black women.

11. Immunohistochemical characteristics of uterine lipoleiomyomas.

12. Functional evidence for two distinct mechanisms of action of progesterone and selective progesterone receptor modulator on uterine leiomyomas.

13. Advances in uterine fibroid research: linking progesterone and the transforming growth factor-β signaling pathway.

14. Characterization of m6A Modifiers and RNA Modifications in Uterine Fibroids.

15. Analysis of Expression of the ANG1, CaSR and FAK Proteins in Uterine Fibroids.

16. In Vivo Effects of Bay 11-7082 on Fibroid Growth and Gene Expression: A Preclinical Study.

17. Targeting the long non-coding RNA MIAT for the treatment of fibroids in an animal model.

18. Psychosocial Stress and MicroRNA Expression Profiles in Myometrial Tissue of Women Undergoing Surgical Treatment for Uterine Fibroids.

19. Raf kinase inhibitor protein expression in smooth muscle tumours of the uterus: a diagnostic marker for leiomyosarcoma?

20. Senescence-associated secretory phenotype (SASP) and uterine fibroids: Association with PD-L1 activation and collagen deposition.

21. POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY.

22. FOXO3a deregulation in uterine smooth muscle tumors.

23. NNMT overexpression is an adverse prognostic factor in uterine leiomyosarcoma.

24. Synergistic inhibition of progesterone receptor-A/B signalling by simvastatin and mifepristone in human uterine leiomyomas.

25. Progesterone signaling in uterine leiomyoma biology: Implications for potential targeted therapy.

26. Killer Function of Circulating Neutrophils in Relation to Cytokines in Uterine Myoma and Endometrial Cancer.

27. Racial disparity in uterine leiomyoma: new insights of genetic and environmental burden in myometrial cells.

28. The Effect of Race/Ethnicity and MED12 Mutation on the Expression of Long Non-Coding RNAs in Uterine Leiomyoma and Myometrium.

29. Pilot study on the impact of HIFU treatment on miRNA profiles in vaginal secretions of uterine fibroids and adenomyosis patients.

30. Immunohistochemical Expression of the SERPINA3 Protein in Uterine Fibroids.

31. Variants in exon 2 of MED12 gene causes uterine leiomyoma's through over-expression of MMP-9 of ECM pathway.

32. Differential Response to Mechanical Cues in Uterine Fibroid Versus Paired Myometrial Cells.

33. Does non-cavity distorting intramural fibroid affect endometrium around the time of embryo implantation?

34. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids.

35. MED12 mutation activates the tryptophan/kynurenine/AHR pathway to promote growth of uterine leiomyomas.

36. Epigenetic Modulation of Inflammatory Pathways in Myometrial Stem Cells and Risk of Uterine Fibroids.

37. Cysteine-rich intestinal protein 1 is a novel surface marker for human myometrial stem/progenitor cells.

38. Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids.

39. Integrating Spatial Transcriptomics and Single-nucleus RNA Sequencing Reveals the Potential Therapeutic Strategies for Uterine Leiomyoma.

40. The Effects of Periostin Expression on Fibroid-Like Transition of Myometrial Cells.

41. Reproductive Functions of the Mitochondrial Progesterone Receptor (PR-M).

42. Importance of Fibrosis in the Pathogenesis of Uterine Leiomyoma and the Promising Anti-fibrotic Effects of Dipeptidyl Peptidase-4 and Fibroblast Activation Protein Inhibitors in the Treatment of Uterine Leiomyoma.

43. Racial differences in transcriptomics and reactive oxygen species burden in myometrium and leiomyoma.

44. Surgical removal of FIGO type 0 and 1 fibroids ameliorates the expression of endometrial proinflammatory transcription factors and receptivity modulators.

45. Adipocyte and Adipokines Promote a Uterine Leiomyoma Friendly Microenvironment.

46. Pivotal Role of Ubiquitin Carboxyl-Terminal Hydrolase L1 (UCHL1) in Uterine Leiomyoma.

47. Adipocyte coculture induces a pro-inflammatory, fibrotic, angiogenic, and proliferative microenvironment in uterine leiomyoma cells.

48. Insulin-Like Growth Factor-1 Promotes Human Uterine Leiomyoma Cell Proliferation via PI3K/AKT/mTOR Pathway.

49. New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.

50. Uterine leiomyoma as useful model to unveil morphometric and macromolecular collagen state and impairment in fibrotic diseases: An ex-vivo human study.

Catalog

Books, media, physical & digital resources